Skip to Main Content

Paper Details

Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma.
Acta Neuropathol
11
2023
Author NameAffiliation
William C ChenUniversity of California San Francisco
William C ChenUniversity of California San Francisco
William C ChenUniversity of California San Francisco
James C BayleyBaylor College of Medicine
Abrar ChoudhuryUniversity of California San Francisco
Abrar ChoudhuryUniversity of California San Francisco
Abrar ChoudhuryUniversity of California San Francisco
Abrar ChoudhuryUniversity of California San Francisco
Abrar ChoudhuryUniversity of California San Francisco
Abrar ChoudhuryUniversity of California San Francisco
Arif HarmanciCenter for Secure Artificial Intelligence For hEalthcare (SAFE), Center for Precision Health, University of Texas Health Science Center Houston
Arif HarmanciCenter for Secure Artificial Intelligence For hEalthcare (SAFE), Center for Precision Health, University of Texas Health Science Center Houston
Akdes Serin HarmanciBaylor College of Medicine
Stephen T MagillNorthwestern University
Stephen T MagillNorthwestern University
David R RaleighUniversity of California San Francisco
David R RaleighUniversity of California San Francisco
David R RaleighUniversity of California San Francisco
David R RaleighUniversity of California San Francisco
David R RaleighUniversity of California San Francisco
David R RaleighUniversity of California San Francisco
Tiemo J KlischJan and Dan Duncan Neurological Research Institute, Texas Children's Hospital
Tiemo J KlischBaylor College of Medicine
Akash J PatelBaylor College of Medicine
Akash J PatelJan and Dan Duncan Neurological Research Institute, Texas Children's Hospital
Akash J PatelBaylor College of Medicine
  • 1 - 26

Datasets